Business Context and Reporting Period
Foghorn Therapeutics Inc. filed this Form 8-K on June 22, 2023, reporting matters from its June 21, 2023 Annual Meeting of Stockholders. The company is a Delaware biotechnology company, and its common stock trades on Nasdaq under ticker FHTX.
Financial and Operating Metrics
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report financial or operational changes versus a prior period. It reports the approval of all matters submitted to stockholders.
Annual Meeting Results, Outlook, and Risks
- Stockholders elected Douglas G. Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall as Class III directors, each for a three-year term.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- There were 41,824,758 shares entitled to vote and 31,292,886 shares present or represented by proxy.
- Director election results included 9,648,103 broker non-votes. Votes for Cole, Gill, and Parshall were 19,470,509, 21,481,572, and 21,600,133, respectively.
- The auditor ratification results were 31,282,179 votes for, 858 against, and 9,849 abstentions, with no broker non-votes.
- The filing provides no new financial guidance, operating outlook, contingencies, or unusual items.
Important Facts for Investors to Verify
- Confirm the three elected directors’ continued service and three-year terms.
- Confirm Deloitte & Touche LLP’s appointment for the fiscal year ending December 31, 2023.
- Review the company’s proxy statement filed April 28, 2023 for detailed proposal information.
- Use the company’s periodic reports, rather than this filing, to assess financial condition, liquidity, cash runway, and clinical or business risks.